YOYoshiki Oitani

Yoshiki Oitani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoshiki Oitani has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Ayako Shioya

    Department of Neurology, Mito Kyodo General Hospital, Tsukuba University Hospital Mito Area Medical Education Center, Japan

    1 shared publication
  • Emiko Morimoto

    Department of Diagnostic and Interventional Radiology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan; Department of Diagnostic Radiology, Osaka City General Hospital, Osaka, Japan

    1 shared publication
  • Eriko Adachi

    Department of Pediatrics and Developmental Biology Institute of Science Tokyo Tokyo Japan

    1 shared publication
  • Fumio Suzuki

    Department of Diagnostic Radiology, TMIG, Tokyo, Japan

    1 shared publication
  • Fumiyo Kato

    Department of Pediatrics, Tokyo Women's Medical University Medical Center East, Tokyo, Japan

    1 shared publication
  • Haruka Kuno

    Department of Pediatrics, Japanese Red Cross Tokyo Katsushika Perinatal Center, Tokyo 125-0051, Japan

    1 shared publication

Latest Publications

  • Open Access

    Congenital adrenal hypoplasia with neurodevelopmental delay due to contiguous Xp21 deletion: a case series with review of literature

    by Maki Gau, Ryosei Iemura, Ryuta Orimoto, Eriko Adachi, Yoko Saito, Haruki Yamano, Hisae Nakatani, Shizuka Kirino, Haruka Kuno, Kengo Moriyama, et al.

    X-linked adrenal hypoplasia congenita (AHC) is a rare, life-threatening disorder caused by pathogenic variants in NR0B1 (DAX1), leading to adrenal insufficiency and hypogonadotropic hypogonadism. AHC is often associated with Xp21 contiguous gene deletion syndrome, which involves the deletion of multiple genes, including NR0B1, GK, DMD, and IL1RAPL1, resulting in a spectrum of phenotypic manifestations, such as glycerol kinase deficiency (GKD), Duchenne muscular dystrophy (DMD), and neurodevelopmental disorders. We report two cases of AHC with neurodevelopmental delays due to contiguous Xp21 deletions involving NR0B1 and IL1RAPL1, each diagnosed through distinct clinical pathways. Case 1 involved a neonate with adrenal insufficiency, persistent hyperCKemia, and excessive urinary glycerol excretion, leading to a diagnosis of Xp21 deletion syndrome with DMD and GKD. The patient’s sister, an asymptomatic carrier, exhibited elevated CK levels and mild developmental delays. Array comparative genomic hybridization identified a novel complex structural variation, including duplication-deletion-duplication rearrangement, which may have modified clinical manifestations. Case 2 involved a 10-year-old boy with AHC and developmental delay that was initially considered a consequence of adrenal crises. Genetic analysis confirmed an Xp21 deletion, including IL1RAPL1, implicating it in his intellectual disability. A literature review reveals that Xp21 deletions involving IL1RAPL1 are strongly associated with neurodevelopmental delays, suggesting a distinct phenotype within Xp21 deletion syndromes. Early genetic diagnosis via chromosomal microarray analysis facilitates precise delineation of deletion regions, aiding in clinical management, genetic counseling, and early intervention strategies. Further studies are needed to elucidate genotype-phenotype correlations in Xp21 deletion syndromes and optimize individualized medical care.


  • Complete remission from post-heart transplant lymphoproliferative disorder: A case report

    by Yoshiki Oitani, Fumiyo Kato, Kaoru Ikeno, Mikiko Ishido, Toshio Nakanishi, Shigetaka Sugihara, Shinichi Nunoda


  • Open Access

    Radiologic and Pathologic Features of the Transmantle Sign in Focal Cortical Dysplasia: The T1 Signal Is Useful for Differentiating Subtypes

    by Yukio Kimura, A Shioya, Y Saito, Y Oitani, Y Shigemoto, E Morimoto, F Suzuki, N Ikegaya, Yuiko Kimura, K Iijima, et al.

    BACKGROUND AND PURPOSE: The transmantle sign is a characteristic MR imaging finding often seen in focal cortical dysplasia type IIb. The transmantle sign is typically hyperintense on T2WI and FLAIR and hypointense on T1WI. However, in some cases, it shows T1 high signal. We evaluated the imaging and pathologic findings to identify the causes of the T1 high signal in the transmantle sign. MATERIALS AND METHODS: We retrospectively reviewed the preoperative imaging data of 141 consecutive patients with histologically proved focal cortical dysplasia. We selected 25 patients with focal cortical dysplasia with the transmantle sign and divided them into groups based on the pathologic focal cortical dysplasia subtype and T1 signal of the transmantle sign. We evaluated the clinical, radiologic, and pathologic findings, including the number of balloon cells and dysmorphic neurons and the severity of gliosis or calcifications and compared them among the groups. RESULTS: Nine of the 25 patients had a T1-high-signal transmantle sign; the other 16 patients did not. All 9 patients with a T1-high-signal transmantle sign were diagnosed as type IIb (group A). Of the 16 patients with no T1-high-signal transmantle sign, 13 were diagnosed as having type IIb (group B), and the other 3 patients, as type IIa (group C). The number of balloon cells was significantly higher in group A than in the other groups, but there were no differences regarding dysmorphic neurons, the severity of gliosis, or calcifications. CONCLUSIONS: Approximately 6% (9/141) of this patient series had a T1-high-signal transmantle sign, and all were type IIb. The signal may reflect a rich density of balloon cells. This finding could support the differentiation of subtypes, especially type IIb.